Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) is a clinical-stage biopharmaceutical company developing treatments for retinal diseases, with TH103 as its lead product candidate. TH103 is an intravitreal, fully humanized anti-VEGF fusion protein designed for longer retention in the eye and enhanced VEGF inhibition. The… From the company’s description.
In fiscal 2025, Kalaris Therapeutics, Inc. reported a net loss of $43.44M. Operations used $38.37M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kalaris Therapeutics, Inc. does
In the company’s own words
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) is a clinical-stage biopharmaceutical company developing treatments for retinal diseases, with TH103 as its lead product candidate. TH103 is an intravitreal, fully humanized anti-VEGF fusion protein designed for longer retention in the eye and enhanced VEGF inhibition. The company is evaluating it in clinical trials for neovascular age-related macular degeneration (nAMD), with potential development for diabetic eye disease and retinal vein occlusion. Its customers would include patients and healthcare providers if its product candidates receive marketing approval; it has not generated product sales. Kalaris operates as a single-focus drug developer, with no reportable business segments described. Its Phase 1b/2 study evaluates repeat TH103 doses in patients with nAMD, following initial Phase 1a testing. The company retains worldwide development and commercialization rights to TH103 and intends to commercialize it through its own specialty salesforce if approved. Kalaris became the successor to AlloVir’s business following a March 2025 merger, after which the company took the Kalaris name. Its website is www.kalaristx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BERKELEY HEIGHTS, NJ
- Fiscal year end
- December
- CIK
- 1754068
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kalaris Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kalaris Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kalaris Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kalaris Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kalaris Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”